Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03939026 | Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma | PHASE1 | COMPLETED | 50 | — | — | May 1, 2019 | Jan 28, 2025 | Mar 2, 2026 | 7 | United States |
Dose limiting toxicity is defined as protocol-defined ALLO-501-related adverse events with onset within 28 days following infusion
Dose-limiting toxicity is defined as protocol-defined ALLO-647-related adverse events with onset within 33 days following 1st infusion
| Arm | Type | Description |
|---|---|---|
| ALLO-647, ALLO-501 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ALLO-501 | GENETIC | ALLO-501 is an allogeneic CAR T cell therapy targeting CD19 |
| ALLO-647 | BIOLOGICAL | ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen |
| Fludarabine | DRUG | Chemotherapy for lymphodepletion |
| Cyclophosphamide | DRUG | Chemotherapy for lymphodepletion |
Inclusion Criteria: * Histological or cytological diagnosis of Large B-cell Lymphoma (LBCL) or Follicular Lymphoma. * Relapse or refractory disease after at least 2 lines of chemotherapy * At least 1 measurable lesion at time of screening. * Eastern Cooperative Oncology Group Performance Status of ...